Alar Pharmaceuticals Inc 6785

TPEX · Taiwan · Health Technology

TWD 94.70-0.60 (-0.63%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Alar Pharmaceuticals Inc 6785

TPEX · Taiwan · Health Technology

TWD 94.70-0.60 (-0.63%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Company news

Yahoo FinanceApr 06, 2026

Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results from its phase 1 clinical study of ALA-3000, a proprietary long-acting, sustained-release ketamine injection for treatment-resistant depression (TRD). This randomized, double-blind, placebo-controlled, multiple-dose first-in-human study evaluated the subcutaneous (SC) administration of ALA-3000 in combination with a sta

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.